Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
A decision on the European marketing authorization extension for the subcutaneous formulation of Opdivo is expected by June 2, 2025 SAN DIEGO , March 31, 2025 /PRNewswire/ -- Halozyme Therapeutics, In
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
11:10am, Friday, 21'st Mar 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Joins the $1 Billion Club
07:35am, Friday, 21'st Mar 2025
Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
12:39pm, Thursday, 13'th Mar 2025
Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in 2024.
HALO vs. AMGN: Which Stock Is the Better Value Option?
12:40pm, Tuesday, 11'th Mar 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best option f
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:41am, Wednesday, 05'th Mar 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
08:30am, Wednesday, 26'th Feb 2025
SAN DIEGO , Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host i
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:45pm, Monday, 24'th Feb 2025
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
10:50am, Thursday, 20'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
10:20am, Wednesday, 19'th Feb 2025
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
07:55pm, Tuesday, 18'th Feb 2025
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
06:31pm, Tuesday, 18'th Feb 2025
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
06:16pm, Tuesday, 18'th Feb 2025
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.82 per share a year ago.
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increa
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
08:30am, Tuesday, 18'th Feb 2025
HOUSTON, TX, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the
